Want to see SYBX full AI Analyst Report?
SYBX Stock Chart & Stats
$1.21
$0.02(1.41%)
At close: 4:00 PM EST
$1.21
$0.02(1.41%)
Day’s Range― - ―
52-Week Range$0.54 - $1.87
Previous CloseN/A
Volume234.00
Average Volume (3M)24.11K
Market Cap
$12.25M
Enterprise Value$4.96M
Total Cash (Recent Filing)$13.18M
Total Debt (Recent Filing)$0.00
Price to Earnings (P/E)―
Beta0.77
Next EarningsN/A
EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)N/A
Shares Outstanding12,248,950
10 Day Avg. Volume49,027
30 Day Avg. Volume24,110
Financial Highlights & Ratios
PEG Ratio0.15
Price to Book (P/B)1.16
Price to Sales (P/S)0.00
P/FCF Ratio-3.16
Enterprise Value/Market Cap0.40
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/Ebitda-1.34
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Zero DebtEliminating debt materially reduces interest obligations, refinancing exposure, and financial stress while the company advances development programs. Positive equity provides some balance-sheet cushion, giving management greater flexibility to direct available resources toward research and clinical priorities.
Lower Cash BurnThe sharp reduction in operating cash burn indicates stronger cost discipline and a more efficient operating base than in earlier periods. Although cash generation remains negative, lower ongoing consumption can extend the usefulness of available funding and reduce the pace of future financing needs.
Merger Financing And Clinical RunwayA substantial financing tied to Phase 2 development gives the combined company resources to advance CLD-423 in ulcerative colitis and Crohn’s disease. Extending runway into 2029 may support clinical execution through meaningful milestones without relying immediately on repeated capital raises.
Bears Say
No Commercial RevenueThe absence of recurring commercial revenue leaves Synlogic dependent on development progress, collaborations, and external financing rather than customer demand for approved products. This limits earnings visibility, operating leverage, and the company’s ability to become self-sustaining over the medium term.
Persistent Negative Free Cash FlowContinued negative free cash flow means the business still consumes capital to operate and advance its programs, even after substantial cost reductions. Without positive internal cash generation, future clinical work remains exposed to financing availability and potential dilution or reliance on strategic transactions.
Shrinking Asset Base And Negative ReturnsThe substantial contraction in assets reflects a much smaller financial base supporting the company’s development activities. Persistent negative returns indicate that capital has not yet produced sustainable economic value, increasing the importance of successful clinical execution and future funding.
Synlogic News
SYBX FAQ
What was Synlogic’s price range in the past 12 months?
Synlogic lowest stock price was $0.54 and its highest was $1.87 in the past 12 months.
What is Synlogic’s market cap?
Synlogic’s market cap is $12.25M.
When is Synlogic’s upcoming earnings report date?
The company’s upcoming earnings report date is not yet available.
How were Synlogic’s earnings last quarter?
Currently, no data Available
Is Synlogic overvalued?
According to Wall Street analysts Synlogic’s price is currently Overvalued.
Does Synlogic pay dividends?
Synlogic does not currently pay dividends.
What is Synlogic’s EPS estimate?
Synlogic’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Synlogic have?
Synlogic has 12,248,950 shares outstanding.
What happened to Synlogic’s price movement after its last earnings report?
Currently, no data Available
Which hedge fund is a major shareholder of Synlogic?
Currently, no hedge funds are holding shares in SYBX
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Synlogic
Synlogic, Inc. does not have significant operations. It was previously engaged in the discovery and development of synthetic biotics to treat metabolic diseases. Synlogic, Inc. is based in Winchester, Massachusetts.
Technical Analysis
Lisata Therapeutics
―
Aptevo Therapeutics
―
SeaStar Medical Holding
―
Cingulate Inc
―
Allarity Therapeutics
―
Ownership Overview
34.63% Insiders
0.04% Mutual Funds
0.19% Other Institutional Investors
65.14% Public Companies and
Individual Investors